Beighton P. The syndromic status of sclerosteosis and van Buchem disease. Clin Genet 1984;25(2):175-81.
Johnson ML. Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13). Am J Hum Genet 1997;60(6):1326-32.
Ross SE. Inhibition of adipogenesis by Wnt signaling. Science 2000;289:950-3.
Balemans W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10(5):537-43.
Brunkow ME. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68(3):577-89.
Gong Y. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513-23.
Nusse R. Developmental biology. Making head or tail of Dickkopf. Nature 2001;411:255-6.
Balemans W. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002;39(2):91-7.
Boyden LM. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:1513-21.
Kato M. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002;157(2):303-14.
Little RD. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002;70:11-9.
Ross SE. Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism. Mol Cell Biol 2002;22:5989-99.
Staehling-Hampton K. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 2002;110(2):144-52.
Hamersma H. The natural history of sclerosteosis. Clin Genet 2003;63(3):192-7.
Kusu N. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003;278(26):24113-7.
Nusse R. Wnts and Hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell surface. Development 2003;130:5297-305.
Rawadi G. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003;18:1842-53.
Tian E. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94.
Van Wesenbeeck L. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003;72:763-71.
Wergedal JE. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 2003;88(12):5778-83.
Wergedal JE. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 2003;88:5778-83.
Willert K. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003;423:448-52.
Winkler DG. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. Embo J 2003;22(23):6267-76.
Johnson ML. LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res 2004;19(11):1749-57.
Kouzmenko AP. Wnt/beta-catenin and estrogen signaling converge in vivo. J Biol Chem 2004;279(39):40255-8.
Mizuguchi T. LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density. J Hum Genet 2004;49:80-6. Epub 2004 Jan 15.
Moon RT. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5(9):691-701.
Sevetson B. Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J Biol Chem 2004;279(14):13849-58.
Sutherland MK. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 2004;35(4):828-35.
Sutherland MK. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 2004;35(2):448-54.
Uitterlinden AG. Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum Genet 2004;75(6):1032-45.
van Bezooijen RL. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004;199(6):805-14.
Winkler DG. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem 2004;279(35):36293-8.
Balemans W. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone 2005;36(6):943-7.
Bellido T. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146(11):4577-83.
Bezooijen RL. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005;16(3):319-27.
Bodine PV. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 2005.
Crabbe P. Missense Mutations in LRP5 Are Not a Common Cause of Idiopathic Osteoporosis in Adult Men. J Bone Miner Res 2005;20(11):1951-9.
Ferrari SL. LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone 2005.
Gardner JC. Bone Mineral Density in Sclerosteosis; Affected Individuals and Gene Carriers. J Clin Endocrinol Metab 2005.
Gaur T. Canonical WNT signaling promotes osteogenesis by directly stimulating RUNX2 gene expression. J Biol Chem 2005.
Hall CL. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65(17):7554-60.
Hartikka H. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 2005;20(5):783-9.
Jackson A. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 2005;36(4):585-98.
Keller H. SOST is a target gene for PTH in bone. Bone 2005;37(2):148-58.
Kulkarni NH. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 2005;95(6):1178-90.
Kwee ML. An autosomal dominant high bone mass phenotype in association with craniosynostosis in an extended family is caused by an LRP5 missense mutation. J Bone Miner Res 2005;20(7):1254-60.
Levasseur R. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 2005;72(3):207-14.
Li X. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280(20):19883-7.
Loots GG. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005;15(7):928-35.
Ott SM. Sclerostin and Wnt signaling--the pathway to bone strength. J Clin Endocrinol Metab 2005;90(12):6741-3.
Poole KE. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 2005.
Poole KE. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb J 2005.
Rickels MR. Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation. J Bone Miner Res 2005;20(5):878-85.
Semenov M. SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor. J Biol Chem 2005;280(29):26770-5.
Shao JS. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005;115(5):1210-20.
Vaes BL. Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts. Bone 2005;36(5):803-11.
Vestergaard P. Reduced Relative Risk of Fractures Among Users of Lithium. Calcif Tissue Int 2005.
Winkler DG. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 2005;280(4):2498-502.
Zhang ZL. Association of polymorphisms in low-density lipoprotein receptor-related protein 5 gene with bone mineral density in postmenopausal Chinese women. Acta Pharmacol Sin 2005;26(9):1111-6.
Krishnan V. Regulation of bone mass by Wnt signaling. J Clin Invest 2006;116(5):1202-9.
van Meurs JB. Common genetic variation of the low-density lipoprotein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men. J Bone Miner Res 2006;21(1):141-50.
Robling AG. Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J Biol Chem 2008;283(9):5866-75.